

nexus/ag



QUARTERLY REPORT
from the 01st of January to
30th of September 2017

Letter to our Stockholders

Dear Stockholders

Continued strong growth, increasing profitability and new, future-oriented projects! The NEXUS-Team is extremely pleased about this positive development in the first nine months of the current year. Against the background of the strong prior-year figures of the high integration costs and the negative exchange rate developments in the Swiss franc, the current result is particularly noteworthy.

NEXUS / NEXT is in the foreground

With a sales increase of approx. 12 % and an increase in earnings before interest and taxes of around 16 %, we again were able to develop growth and improved results in parallel very successfully.


We were more than able to compensate for the still small number of new HIS bid invitations thanks to strong development of business with existing customers and sale of ward solutions. We also received numerous orders in the diagnostic field, in particular in the areas of radiology (the new NEXUS / RIS), endoscopy and cardiology (CWD). We were able to acquire more customers for complete HIS solutions, especially in France and Germany. All in all, the number of new orders continued to increase in the first nine months.

We are currently implementing a few outstanding projects. This certainly includes the order from the „Central Medical Service of the German Armed Forces“ (ZSanDstBw). We are implementing a pilot project for the future digital supply of soldiers in the field. The field hospital operated under German management in multinational foreign deployments is to receive the software support customary in Germany via NEXUS systems in the future. The systematic digitalization of the health records of the soldiers is an important objective of the Central Medical Service. Our project in Cyprus is also very interesting. We are installing our radiooncology solution in a state-of-the-art radiotherapy clinic. We are also working intensively on our solution for endoscopic documentation in gastroenterology. This joint development with the medical technology company Olympus is aimed at the European market. We are already well advanced here and in the middle of the sales phase.


Highlights 3rd Quarter - 2017 Company development

- + Strong development of sales in the first nine months
- + German military pilot project for the “digital supply of soldiers in the field” running according to plan
- + Majority acquisition of a client management software provider (highsystem AG).
- + Olympus: sales running parallel in several countries

Development of Group Sales (9 months) in KEUR 2008-2017



Development of EBIT (Group Earnings before Interest and Taxes) (9 months) in KEUR 2008-2017



These projects are part of our NEXT / NEXUS program and consequently the focus of corporate strategy. The new NEXT / NEXUS software generation is not only a further technical development, but in particular the implementation of a completely intuitive user interface. The software provides process-oriented screen layouts that users can easily navigate and which can be customized. We are taking the new and bold step to design our software completely process-oriented and user-related. Success has shown that we are on the right path. In 2017, we launched three new overall projects (NEXUS / HIS^{NG}) and put approx. 19 NEXT GENERATION installations into operation in the areas of patient management, radiology and ECM.

Another component of the NEXT / NEXUS program is the completion of our product range. In the current year, we have strengthened our position in the fields of telemedicine and radiology with the acquisition of 51 % of the shares of CHILI GmbH, Dossenheim. Telemedical applications are increasingly in demand in Germany and many European countries. The lack of doctors, the need for second opinions and cost optimization are the main reasons for the appeal of telemedicine. CHILI solutions are considered a benchmark in digital radiology and in nationwide networking of healthcare organizations. In August, we were also able to acquire a majority share in the company highsystem AG for the NEXUS: a small team with excellent expertise and a software solution in the field of life-cycle client management. This is an important function in the operation of our customer platforms.

Dear Shareholders, NEXUS continues to show healthy growth, good development of results, and is consistently pursuing its core topics of „NEXT / NEXUS“ and „European Expansion“. However, our goal of developing NEXUS in an internationalized structure into the leading European provider of e-health solutions remains the same in all aspects. We are also aware that we are taking significant risks with this innovative and expansive course. The current projects, integration tasks and ongoing expansion especially present great challenges for us. But we are convinced that we are on the right path and are working ambitiously on this future strategy.

We want to thank you, dear Shareholders, for your trust.

Warm regards,

Dr. Ingo Behrendt
CEO



Financial Highlights

for the 3rd Quartar 2017 und 2016

	30/09/2017	30/09/2016	Changes
	KEUR	KEUR	%
Sales	86,282	77,308	11.6
Sales Healthcare Software	78,047	70,905	10.1
Sales Healthcare Service	8,235	6,403	28.6
Domestic sales	47,228	39,380	19.9
Sales in foreign countries	39,054	37,928	3.0
Earnings before tax on income (EBT)	8,777	7,603	15.4
Earnings before interest and taxes on earnings (EBIT)	8,772	7,571	15.9
EBITA	10,699	9,453 ¹⁾	13.2
EBITDA	16,101	14,596	10.3
Consolidated surplus	7,425	6,533	13.7
Cash Flow from current business transactions	19,856	15,356	29.3
Net income per share (undiluted/diluted) in EUR	0.46 / 0.46	0.40 / 0.40	15.0 / 15.0
Share price (closing price, XETRA) in EUR	25.96	18.43	40.9
Capitalization of software developments	3,749	3,989	-6.0
Depreciation	7,329	7,025	4.3
Acquisition-related depreciations from purchase price allocation	1,927	1,882	2.4
Fixed Assets (without deferred taxes)	95,570	92,949 ²⁾	2.8
Current Assets / Short-Term Assets	54,643	48,025	13.8
Net Liquidity	27,516	20,235	36.0
Equity Capital	100,742	95,802 ²⁾	5.2
Employees (as of the out-off date)	960	902	6.4

¹⁾ adjusted

²⁾ out-off date 31 December 2016

Interim Annual Report

Report about the Profit, Financial and Asset Situation

NEXUS Group sales increased from KEUR 77,308 to KEUR 86,282 (+11.6 %) in the first nine months of the year 2017.

As a result, the sustained steady good sales development of the NEXUS Group of recent years could be continued in the first nine months of 2017. Sales increased from KEUR 70,905 to KEUR 78,047 (+10.1 %) in the Healthcare Software Division. Sales increases of +28.6 % were achieved in the Healthcare Service Division (9M-2017: KEUR 8,235; 9M-2016: KEUR 6,403). The strong increase in the Healthcare Service Division is on the one hand thanks to reclassifications in revenue allocation, but also especially thanks to new orders for overall IT customer support.

The picture within the national organizations is mixed. We were able to increase sales in Germany by 19.9 % to KEUR 47,228 (9M-2016: KEUR 39,380). In international business, we recorded sales of KEUR 39,054 from January to September 2017 compared to KEUR 37,928 (9M-2016) (+3.0 %). The decline in sales was negatively impacted in the Netherlands (-15.5 %); we settled major projects in the previous-year period there, which produced a seasonal effect.

There were negative sales effects from exchange rate fluctuations of the Swiss franc in the amount of KEUR -91. The average exchange rate of the Swiss franc of SFR 1.0952 on 30 September 2017 was slightly above the average price on 31 December 2016 (SFR 1.0902). Thanks to the integration of CHILI GmbH, Dossenheim, and highsystem AG, Zurich, acquired in 2017, we were able to consolidate an overall increase in revenue of EUR 1.90 million as of 1 June 2017 and 1 September 2017.


The result before taxes and interest (EBIT) also developed very strongly. KEUR 8,772 (9M-2017) were recorded and consequently an increase of 15.9 % compared to the previous year (9M-2016: KEUR 7,571). A value of KEUR 10,699 was achieved in EBITA and consequently was 13.2 % above the value of previous year (9M-2016 adjusted: KEUR 9,453). EBITDA amounts to KEUR 16,101, which represents an increase of 10.3 % compared to the previous year (9M-2016: KEUR 14,596).

The cash flow from ongoing business transactions developed positively. At KEUR 19,856, the cash flow was 29.3 % higher than the comparable period of the previous year (9M-2016: KEUR 15,356). The reasons for this are the higher business volume and incoming payments from maintenance revenues.


The consolidated surplus increased by 13.7 % from KEUR 6,533 (9M-2016) to KEUR 7,425. Earnings per share were EUR 0.46 (9M-2016: EUR 0.40).

Cash and cash equivalents including securities amounted to KEUR 27,516 on 30 September 2017 (30 June 2016: KEUR 20,235).

EBITDA (9 months) in KEUR
+10.3 % compared to previous year



Cash Flow from current business transactions (9 months) in KEUR
+29.3 % compared to previous year



Investments in tangible and intangible assets were made in the amount of KEUR 6,183 in the first nine months of 2017 (9M-2016: KEUR 7,886). This includes KEUR 3,749 (9M-2016: KEUR 3,989) for capitalizing software developments.

The balance sheet total increased from KEUR 139,641 to KEUR 152,721 (30 September 2017) compared to 31 December 2016. There are no essential bank liabilities. Intangible assets, goodwill and balanced-out deferred taxes add up to a total of KEUR 82,483 following KEUR 81,576 (31 December 2016). Receivables from customers increased slightly from KEUR 21,170 (30 September 2016) to KEUR 21,389.

Employees

NEXUS Group employed a total of 960 people as of 30 September 2017 (30 September 2016: 902 employees). A total of 870 employees (30 September 2016: 820) are employed in the Healthcare Software Division. The Healthcare Service Division employed 90 people (30 September 2016: 82).

Annual Stockholders Meeting and Dividends

At the Annual Stockholders Meeting of NEXUS AG in Stuttgart on 12 May 2017, the Executive Board and Supervisory Board proposed to pay a one cent higher dividend of 0.15 EUR to shareholders than the previous year from the retained earnings of fiscal year 2016. The proposal was adopted by the required majority. Consequently, there was a total distribution of KEUR 2,358.

Financial Highlights 3rd Quarter - 2017

- + 11.6 % increase in sales from KEUR 77,308 (9M-2016) to KEUR 86,282 (9M-2017)
- + 15.9 % increase of EBIT from KEUR 7,571 (9M-2016) to KEUR 8,772 (9M-2017)
- + 29.3 % increase of operative cash flow: KEUR 19,856 (9M-2017) following KEUR 15,356 (9M-2016)
- + € 7.3 million increase in cash and cash equivalents to KEUR 27,516 (30 September 2016: KEUR 20,235).

Events after the Balance Sheet Date

In partial utilization of empowerment for the period until 30 April 2021, to increase the share capital once or several times by up to a total of Euro 3,000,000.00 through the issue of up to 3,000,000 new bearer shares against cash or contributions in kind (authorized capital 2016 / I) adopted on 13 May 2016 by the general meeting of NEXUS AG, the Executive Board decided on 14 July 17 with the consent of the Supervisory Board of the same day to increase the share capital of the company against cash under exclusion of subscription rights of shareholders—in favor of employees of NEXUS AG and affiliated companies of NEXUS AG—from 15,735,665,00 by 25,000.00 euros to 15,760,665,00 through the issue of up to 25,000 new bearer shares with a share in the company of 1.00 euro each and with profit entitlement starting from 1 January 2017. The registration of the implementation of the capital increase was made in the commercial register at the Freiburg Register of Companies (Commercial Register No. 602434) on 27 October 2017. Capital stock increased by EUR 16,566.00 to EUR 15,752,231.00. As a result, authorized capital 2016/I is still EUR 2,983,434.00 after partial exploitation.

Sales by region

	01/01-30/09/17	01/01-30/09/16	Changes	01/07-30/09/17	01/07-30/09/16	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Germany	47,228	39,380	19.9	16,605	13,782	20.5
Switzerland	21,201	19,939	6.3	6,326	6,235	1.5
Netherlands	10,170	12,038	-15.5	3,077	3,462	-11.1
France	3,881	3,910	-0.7	1,213	1,138	6.6
Austria	1,471	1,019	44.4	299	474	-36.9
Other countries	2,331	1,022	128.1	632	413	53.0
Total	86,282	77,308	11.6	28,152	25,504	10.4

Sales by devision

	01/01-30/09/17	01/01-30/09/16	Changes	01/07-30/09/17	01/07-30/09/16	Changes
	KEUR	KEUR	%	KEUR	KEUR	%
Healthcare Software	78,047	70,905	10.1	25,602	23,163	10.5
Healthcare Service	8,235	6,403	28.6	2,551	2,341	9.0
Total	86,282	77,308	11.6	28,153	25,504	10.4



nexus / **his**^{NG}

100 % Individual Workspaces.

Customize your workspace according to your way of working in the new NEXUS / HIS^{NG}. You decide how you document your rounds, structure your medication processes, record case histories or write your findings as well as how your work steps are linked. Menu trees and function searches are a thing of the past. Your workspace is your personal home.

You can learn more about your NEXT GENERATION-HIS from NEXUS at www.nexus-ag.de.

nexus / **his**^{NG} – NEXT GENERATION SOFTWARE FROM NEXUS

NEXUS Group Information and Outlook

Chances and Risks Report

Please refer to the explanations in the annual report of 31 December 2016 for information about the essential chances and risks in the development of NEXUS Group. There have been no essential changes in the meantime.

Ausblick: Stay on the Ball

We were again able to confirm our strong and continuous development of recent years in the first nine months of 2017. Sales increased by approx. 12 %, earnings before interest and taxes by approx. 16 %, and the operating cash flow increased greatly by 29 % to approx. € 20 million.

In addition: we have been able to successfully implement our objectives and measures until now, which we set for 2017. In addition to the NEXT / NEXUS program, these include the internationalization and integration projects of the acquired companies. We see considerable potential for improvement in the use of shared technologies, tools and processes. This is especially true since our position as an innovative European e-health company is based on the exchange of products, knowledge and technologies between the European NEXUS teams.

Overall, we are promoting the performance of our organization further. It will not be any less for the fourth quarter. We need to implement the further „launch“ of our NEXT / NEXUS program, conclude essential large-scale projects in accordance and complete the integration of new teams and products at the same time. However, our joint development with Olympus will also create new challenges in the fourth quarter.

As a result, we continue to face a challenging strategic program, in which we must succeed in maintaining a focus on revenues and earnings. This is a path that is associated with considerable risks. However, „Stay on the Ball“ is a prerequisite for continuing our exceptional development.

Accounting and Valuation Methods

This interim report from the NEXUS Group of 30 September 2017 has been prepared in keeping with the International Financial Reporting Standards (IFRS) as they are applied in the EU. The interpretations of the International Financial Reporting Interpretation Committee (IFRIC) have been taken into account.

The regulations of IAS 34 were observed in the interim report of 30 September 2017. This refers to a summarized report, which does not contain all information of an IFRS Group Financial Statement, and consequently this report should be read in connection with the Appendix of the Group Financial Statement 2016. The same accounting and valuation methods were used in the Group Financial Statement for the business year 2016.

The report has not been audited.

The Annual Report 2016 and Half-Year Report as of 30 September 2017 could be downloaded on www.nexus-ag.de.

Director's Holdings

The director's holders of the Supervisory Board and the Executive Board are as follows on 30 September 2017 in comparison to the previous year: cf. Table.

Supervisory Board	Number of shares held	Numbers of options
Dr. jur. Hans-Joachim König	89,900 Previous Year (89,900)	0 Previous Year (0)
Prof. Dr. Alexander Pocsay	121,500 Previous Year (121,500)	0 Previous Year (0)
Prof. Dr. Ulrich Krystek	0 Previous Year (0)	0 Previous Year (0)
Wolfgang Dörflinger	0 Previous Year (0)	0 Previous Year (0)
Gerald Glasauer	0 Previous Year (0)	0 Previous Year (0)
Prof. Dr. med Felicia M. Rosenthal	315 Previous Year (315)	0 Previous Year (0)

Executive Board	Number of shares held	Numbers of options
Dr. Ingo Behrendt	111,900 Previous Year (111,900)	0 Previous Year (0)
Ralf Heilig	137,650 Previous Year (137,650)	0 Previous Year (0)
Edgar Kuner	250,351 Previous Year (250,351)	0 Previous Year (0)

Capital market, event and finance data

Investor Relations

Active communication with our stockholders, potential investors, analysts and the finance market are the focal point of our investor relation activities. We continually inform all market participants promptly and comprehensively via press releases and ad hoc announcements as well as the mandatory quarterly, semi-annual and annual financial reports.

In addition, we cultivate intensive dialog with institutional investors and finance analysts via one-on-one meetings and on roadshows. Our Investor Relations team is of course at your disposal as contact persons.

Frankfurt Stock Exchange stock prices (1-year period)



Stock Market Highlights (XETRA closing prices)

- + Initial listing on 02 January 2017: 17.60 €
- + Highest price on 23 June 2017: 28.44 €
- + Stock market capitalization 30 September 2017: 408.5 million. €

30. Nov. - 02. December 2017

German Congress for Perinatal Medicine, Berlin

12. - 14. January 2018

Bamberger Morphology Days, Bamberg

18. - 20. January 2018

CT Symposium, Garmisch-Partenkirchen

26. - 28. February 2018

DRV Rehab-Colloquium, Munich

06. - 08. March 2018

Altenpflege, Hannover

13. - 15. March 2018

INFORSALUD, Madrid (Spain)

28. - 29. March 2018

CEFH, Strasbourg (France)

17. - 19. April 2018

conhIT, Berlin

07. November 2017

Quarterly Report Q3 / 2017

27. - 29. November 2017

Analyst Event, Frankfurt

06. März 2018

Release of Annual Report 2017

More IR events for the year 2018 will be announced with the release of the annual report 2017

Group profit and loss account

for the period from 01 January to 30 September 2017 and 2016

	01/01- 30/09/2017	01/01- 30/09/2016	01/07- 30/09/2017	01/07- 30/09/2016
	KEUR	KEUR	KEUR	KEUR
Revenue	86,282	77,308	28,153	25,504
Development work capitalized	3,749	3,989	1,009	1,347
Other operating income	1,854	1,302	659	653
Cost of materials including purchased services	14,677	11,656	4,220	4,385
Personnel costs	50,760	45,773	16,797	15,125
Depreciation	7,329	7,025	2,370	2,501
Other operating expenses	10,347	10,574	3,549	2,870
Operating Results	8,772	7,571	2,885	2,623
Finance income	70	57	8	1
Finance Expenses	65	25	7	-65
Result before Tax on Profit	8,777	7,603	2,886	2,689
Taxes on profit	1,352	1,070	442	675
Consolidated surplus	7,425	6,533	2,444	2,014
of the consolidated surplus, accounted to:				
- Stockholders of NEXUS AG	7,197	6,287	2,441	1,945
- Shares of non-controlling partners	228	246	3	69
Consolidated net earnings per share in EUR				
Weighted average (undiluted / diluted) of issued shares in circulation (in thousands)	15.734 / 15.785	15.718 / 15.761	15.734 / 15.785	15.718 / 15.761
Undiluted / diluted	0.46 / 0.46	0.40 / 0.40	0.16 / 0.16	0.12 / 0.12

Group Statement of Consolidated Income

for the period from 01 January to 30 September 2017 and 2016

	01/01- 30/09/2017	01/01- 30/09/2016	01/07- 30/09/2017	01/07- 30/09/2016
	KEUR	KEUR	KEUR	KEUR
Consolidated surplus	7,425	6,533	2,444	2,014
Actuarial profits and losses	477	-53	-4	-3
Tax effects	-179	38	-50	-1
Currency conversion differences	-831	-78	1,058	-118
Other Overall Results	-533	-93	1,004	-122
Overall Result of the Period	6,892	6,440	3,448	1,892
of the overall result of the period, accounted to:				
- Stockholders of NEXUS AG	6,674	6,194	3,371	1,823
- Shares of non-controlling partners	218	246	77	69

Consolidated Balance Sheet

as of 30 September 2017 and 31 December 2016

Assets	30/09/2017	31/12/2016
	KEUR	KEUR
Long-Term Assets		
Goodwill	48,988	46,951
Other intangible assets	36,728	37,168
Fixed (Intangible) assets	9,290	8,508
Shares in companies valuted at equity	34	34
Deferred tax assets	2,508	3,085
Other financial assets	530	288
Total of Long-Term Assets	98,078	96,034
Short-Term Assets		
Inventories	826	1,201
Trade receivables and other receivables	21,389	20,132
Receivables from tax on profits	1,267	904
Other non-financial assets	3,186	2,096
Other financial assets	459	418
Short-term financial assets	1,943	2,933
Cash and balance in bank	25,573	15,923
Total of Short-Term Assets	54,643	43,607
Balance Sheet Total	152,721	139,641

Equity and Liabilities	30/09/2017	31/12/2016
	KEUR	KEUR
Equity Capital		
Subscribed capital	15,736	15,736
Capital reserves	34,675	34,307
Retained earnings*	48,820	42,414
Consolidated surplus	7,197	8,146
Other cumulated Group result	-5,896	-4,755
Own shares	-246	-244
Equity capital attributable to stockholders of the parent company	100,286	95,604
Shares of non-controlling partners	456	198
Total Equity Capital	100,742	95,802
Long-Term Debts		
Pension obligations	11,433	11,574
Deferred tax liabilities	5,741	5,628
Other financial debts	4,683	4,521
Total of Long-Term Debts	21,857	21,723
Short-Term Debts		
Accruals	1,206	978
Financial liabilities	3,357	5,678
Liabilities from tax on profit	1,105	2,082
Deferred revenue	9,465	2,120
Other non-financial debts	7,498	6,293
Other financial debts	7,491	4,965
Total of Short-Term Debts	30,122	22,116
Balance Sheet Total	152,721	139,641

* The equity capital position of "Profit carried forward" was changed to "Retained earnings" in the fiscal year to increase transparency.

Consolidated Cash Flow Statement

for the period from 01 January to 30 September 2017 and 2016

	2017	2016
	KEUR	KEUR
1. Cash Flow from Current Business Transactions		
Group annual result before tax on income	8,777	7,603
Write-offs (+) write-ups (-) on intangible assets, tangible assets and financial assets	7,329	7,025
Other expenses not affecting payment (+) / revenue (-)	308	591
Increase (-) / decrease (+) in inventories	390	-280
Gain (-) / loss (+) on disposal of fixed assets and securities	180	82
Increase (-) / decrease (+) in receivables and other assets from operating activities	-1,532	-509
Increase (-) / decrease (+) of accruals insofar as not entered in other comprehensive income	-590	-74
Increase (+) / decrease (-) in liabilities from operating activities	6,440	1,316
Paid interest (-)	-25	-26
Received interest (+)	70	61
Taxes on profit paid (-)	-1,546	-584
Taxes on profit received (+)	55	151
	19,856	15,356
2. Cash Flow from Investment Activities		
Payments (-) for investments in intangible and fixed assets	-6,183	-7,886
Payments (-) for the acquisition of companies consolidated minus cash acquired	-3,084	-5,912
Payments (-) / receipts (+) from the acquisition/disposal of short-term financial assets	1,000	0
	-8,267	-13,798
3. Cash Flow from Financial Activities		
Dividends paid (-)	-2,358	-2,202
Payments (-) for the acquisition of own shares	-50	0
Receipts (+) from the sales of own shares	21	9
	-2,387	-2,193
Cash relevant changes in cash and cash equivalent (sum of 1 + 2 + 3)	9,202	-635
Exchange rate changes on cash and cash equivalents	448	-12
Cash and cash equivalents at beginning of period	15,923	18,185
Cash and cash equivalents at the end of period	25,573	17,538
Composition of cash and cash equivalents		
Liquid funds	25,573	17,538
	25,573	17,538

Group Statement of Changes in Equity

as of 30 September 2017 and 31 December 2016

	Subscribed capital	Capital reserves	Retained earnings*	Annual Net profit	Equity capital difference from currency conversion	Pension reserves	Own shares	Equity capital attributable to stock of parent company	Shares of non-controlling partners	Equity capital total	Authorized Capital
	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR	KEUR
Consolidated equity as of 01/01/2016	15,736	34,044	37,034	7,583	2,585	-7,627	-37	89,318	-258	89,060	5,722
Position of consolidated surplus 2015 in the Group profit carried forward			7,583	-7,583				0		0	
Actuarial profits and losses						-53		-53		-53	
Deferred taxes entered in other comprehensive income						44		44		44	
Currency differences			919		-1,004	1		-84	-4	-88	
Other comprehensive income after taxes as of 30/09/2016	0	0	919	0	-1,004	-8	0	-93	-4	-97	0
Consolidated surplus 9M-2016				6,287				6,287	246	6,533	
Overall Result of the Period	0	0	919	6,287	-1,004	-8	0	6,194	242	6,436	0
Dividend payment			-2,202					-2,202		-2,202	
Sales of own shares		8					1	9		9	
Stock-Based Payment		197						197		197	
Consolidated equity as of 30/09/2016	15,736	34,249	43,334	6,287	1,581	-7,635	-36	93,516	-16	93,500	5,722
Consolidated equity as of 01/01/2017	15,736	34,307	42,414	8,146	2,827	-7,582	-244	95,604	198	95,802	3,000
Posting of consolidated surplus 2016 in the Group profit carried forward			8,146	-8,146				0		0	
Actuarial profits and losses						471		471	6	477	
Deferred taxes entered in other comprehensive income						-178		-178	-2	-179	
Currency differences			618		-1,325	-110		-817	-14	-831	
Other comprehensive income after taxes 30/09/2017	0	0	618	0	-1,325	184	0	-523	-10	-534	0
Consolidated surplus 9M-2017				7,197				7,197	288	7,425	
Overall Result of the Period	0	0	618	7,197	-1,325	184	0	6,674	218	6,892	0
Dividend payment			-2,358					-2,358		-2,358	
Purchase of own shares		-47					-3	-50		-50	
Sale of own shares		20					1	21		21	
New minority interests									40	40	
Stock-Based Payment		395						395		395	
Consolidated equity as of 30/09/2017	15,736	34,675	48,820	7,197	1,502	-7,398	-246	100,286	456	100,742	3,000

* The equity capital position of "Profit carried forward" was changed to "Retained earnings" in the fiscal year to increase transparency.

Declaration according to § 37y No. 1 WpHG

To the best of our knowledge, and in accordance with the applicable reporting principles for interim financial reporting, the interim consolidated financial statements give a true and fair view of the assets, liabilities, financial position and profit or loss of the group, and the interim management report of the group includes a fair review of the development and performance of the business and the position of the group, together with a description of the principal opportunities and risks associated with the expected development of the group for the remaining months of the financial year.

Donaueschingen, 07 November 2017

NEXUS AG
The Executive Board

nexus / ag

NEXUS AG, Irmastraße 1, D-78166 Donaueschingen
Phone +49 771 22960-0, Fax +49 771 22960-226
www.nexus-ag.de, info@nexus-ag.de